secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001437749-24-022658
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
--------------------------------------------------------------------------------

- Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies fully enrolled; topline data expected December 2024.
- KOL event on July 23, 2024 features John-Paul Taylor (Newcastle Univ.) and Ralph A. Nixon (NYU Grossman School of Medicine).
- Agenda includes DLB disease state, neflamapimod mechanism, plasma phosphorylated tau patient selection, and trial design.
- Live Q&A session moderated by CervoMed CEO John Alam following the formal presentations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924022658/0001437749-24-022658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924022658/crvo20240711_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer